Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL8094844 | 0.96 | TDP1 (0.67) | TDP1MAPTL3MBTL1LMNAHDAC1 | |
| SCHEMBL2209431 | 0.86 | TDP1 (0.64) | TDP1MAPTL3MBTL1LMNAHDAC1 | |
| SCHEMBL7068671 | 0.86 | TDP1 (0.95) | TDP1MAPTL3MBTL1LMNAHDAC1 | |
| SCHEMBL1052631 | 0.86 | TDP1 (0.86) | TDP1MAPTL3MBTL1LMNAHDAC1 | |
| SCHEMBL94885 | 0.84 | L3MBTL1 (0.75) | TDP1MAPTL3MBTL1LMNAHDAC1 | |
| SCHEMBL9057671 | 0.84 | TDP1 (1.00) | TDP1MAPTL3MBTL1LMNAHDAC1 | |
| SCHEMBL8519287 | 0.84 | TDP1 (1.00) | TDP1MAPTL3MBTL1LMNAHDAC1 | |
| SCHEMBL27516050 | 0.84 | TDP1 (1.00) | TDP1MAPTL3MBTL1LMNAHDAC1 | |
| SCHEMBL95197 | 0.83 | TDP1 (0.79) | TDP1MAPTL3MBTL1LMNAHDAC1 | |
| SCHEMBL28065139 | 0.82 | TDP1 (0.78) | TDP1MAPTL3MBTL1LMNAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0213883-B1 | NOVEL RADIOACTIVE AND NON-RADIOACTIVE IODOBUTYROPHENONE DERIVATIVE AND PROCESSES FOR THE PREPARATION THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-11-02 | — | — | EP | claimed |
| JP-56157858-A | — | — | None | — | — | JP | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2582701-B1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | ALTOS THERAPEUTICS LLC (US) | 2016-11-02 | — | — | EP | disclosed |
| CN-103052636-B | D 2antagonist and synthetic method thereof and using method | Altos Therapeutics, LLC (US) | 2016-03-09 | — | — | CN | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| EP-0788478-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013484-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-09 | — | — | WO | disclosed |
| US-5380736-A | Cholecystokinin and gastric antagonist | ELF SANOFI (FR) | 1995-01-10 | — | — | US | disclosed |
| US-5314889-A | Hormone antagonists | ELF SANOFI (FR) | 1994-05-24 | — | — | US | disclosed |
| EP-0518731-A1 | Heterocyclic derivatives of substituted 2-acylamino 5-thiazole, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-12-16 | — | — | EP | disclosed |
| US-4739060-A | Radioactive and non-radioactive iodobutyrophenone derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-04-19 | — | — | US | disclosed |
| EP-0213883-A1 | Novel radioactive and non-radioactive iodobutyrophenone derivative and processes for the preparation thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-03-11 | — | — | EP | disclosed |
| JP-S56157858-A | MEASURING METHOD FOR BUTYLOPHENON MEDICINES IN ORGANISM SAMPLE IN WHICH RADIOACTIVE IODIZED BUTYPHENON DERIVATIVE IS USED AS MARK ANTIGEN | SUMITOMO CHEM CO LTD | 1981-12-05 | — | — | JP | disclosed |
| US-4022786-A | PHARMACEUTICALS, CNS STIMULANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-10 | — | — | US | disclosed |
| US-4016280-A | 4,4-Diarylpiperidine compositions and use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | TDP1 4179/4885MAPT 3767/4885L3MBTL1 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.